Sep 8, 2022 Press Releases
PDF Version AT-01 is a first-in-class pan-amyloid imaging agent capable of detecting diverse types of systemic amyloidosis in multiple organs Sensitivity in those with previously diagnosed cardiac disease was 100% in ATTR and 93% in AL Organ-specific changes in...
Sep 7, 2022 Press Releases
PDF Version AT-04 demonstrates potent binding and promotes phagocytosis in ATTR and AL amyloidosis AT-04 binds potently to Aβ, tau, and α-synuclein, common amyloid pathologies in CNS disorders such as Alzheimer’s SAN FRANCISCO, Calif. – September 7, 2022 –...
Sep 6, 2022 Press Releases
PDF Version Human CAR-M cells can be generated with the pan-amyloid reactive p5 peptide as the target amyloid recognition element This novel system may serve as an adjunct to anti-amyloid monoclonal antibodies for the enhanced clearance of tissue amyloid SAN...
Sep 6, 2022 Press Releases
PDF Version AT-02 demonstrates amyloid reduction from the heart, kidney, liver, and spleen AT-02 induces in vivo macrophage-mediated phagocytosis of amyloid fibrils AT-02 binds potently to multiple types of amyloid including ATTR, AL, and ALECT2 SAN FRANCISCO, Calif....
Aug 22, 2022 Press Releases
PDF Version SAN FRANCISCO, Calif. – August 22, 2022 – Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that new data across the Company’s...
